Xenetic Biosciences (XBIO) Free Cash Flow (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Free Cash Flow came in at -$536377.0 in Q1 2026, up 46.46% YoY from -$366218.7 in Q1 2025, and up 3.63% on a QoQ basis from -$556603.0 in Q4 2025.
Xenetic Biosciences (XBIO) Free Cash Flow (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Free Cash Flow data on file, last reported at -$536377.0 in Q1 2026.
- Quarterly Free Cash Flow rose 46.46% year-over-year to -$536377.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 9.18% YoY) and the FY2025 annual result came in at -$2.3 million, down 8.22% from the prior year.
- Free Cash Flow rose to -$536377.0 in Q1 2026, from -$556603.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $30439.0 in Q4 2024 to a low of -$2.1 million in Q1 2022.
- A 5-year average of -$819847.1 and a median of -$726028.0 in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow jumped 102.75% — and 2025, when it slumped 1928.59%.
- Tracing XBIO's Free Cash Flow over 5 years: stood at -$411987.0 in 2022, then tumbled by 168.69% to -$1.1 million in 2023, then jumped by 102.75% to $30439.0 in 2024, then tumbled by 1928.59% to -$556603.0 in 2025, then advanced by 3.63% to -$536377.0 in 2026.
- The last three Free Cash Flow figures came in at -$536377.0 (Q1 2026), -$556603.0 (Q4 2025), and -$658247.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | -875,489.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -875,489.00 |
| Jun 30, 2026 | -875,489.00 |
| Mar 31, 2026 | -536,377.00 |
| Mar 31, 2026 | -536,377.00 |
| Dec 31, 2025 | -556,603.00 |
| Dec 31, 2025 | -556,603.00 |
| Sep 30, 2025 | -658,247.00 |
| Sep 30, 2025 | -658,247.00 |
| Jun 30, 2025 | -383,830.00 |
| Jun 30, 2025 | -383,830.00 |
| Mar 31, 2025 | -1.00 Mn |
| Mar 31, 2025 | -1.00 Mn |
| Dec 31, 2024 | 30,439.00 |
| Dec 31, 2024 | 30,439.00 |
| Sep 30, 2024 | -459,037.00 |
| Sep 30, 2024 | -459,037.00 |
| Jun 30, 2024 | -525,104.00 |
| Jun 30, 2024 | -525,104.00 |
| Mar 31, 2024 | -1.16 Mn |
| Mar 31, 2024 | -1.16 Mn |